©2024 Stanford Medicine
68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors
Not Recruiting
Trial ID: NCT01980732
Purpose
The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.
Official Title
68Ga DOTA-TATE PET/CT in the Evaluation of Patients With Somatostatin Receptor Positive Tumors
Stanford Investigator(s)
Andrei Iagaru
Professor of Radiology (Nuclear Medicine)
Eligibility
Inclusion Criteria:
* Greater than 18 years-old at the time of radiotracer administration
* Provides written informed consent
* Known diagnosis of NET or suspected SSTR positive tumors by 111In-Octreotide scan, 18FDG-PET, or MRI of the abdomen when clinically indicated
* Karnofsky score greater than 50 or ECOG Performance Status 0-2
* Women of childbearing age must have a negative pregnancy test at screening/baseline
* Able to remain still for duration of each imaging procedure (about one hour)
Exclusion Criteria:
* Less than 18 years-old at the time of radiotracer administration
* Pregnant or nursing
* Serum creatinine \>3.0 mg/dL
* Hepatic enzyme levels more than 5 times upper limit of normal.
* Use of any other investigational product or device within 30 days prior to dosing, or known requirement for any other investigational agent prior to completion of all scheduled study assessments.
* Inability to lie still for the entire imaging time
* Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
* Any additional medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance.
Intervention(s):
drug: 68Ga-DOTA TATE
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Krithika Rupnarayan
650-736-0959